2026 FDA Public Meeting on Ralinepag NDA Submission

The 2026 FDA Public Meeting on Ralinepag NDA Submission is a forthcoming event organized by the U.S. Food and Drug Administration (FDA). This meeting will focus on the New Drug Application (NDA) submission for ralinepag, a next-generation, once-daily oral prostacyclin receptor agonist developed for the treatment of pulmonary arterial hypertension (PAH). The event aims to provide a platform for stakeholders to discuss the clinical data, efficacy, and safety profile of ralinepag, as well as its potential role in the PAH treatment landscape.

Key topics to be covered include the results of the phase 3 ADVANCE OUTCOMES study, which demonstrated a 55% reduction in the risk of clinical worsening events compared to placebo, and significant improvements in six-minute walk distance and NT-proBNP levels. Discussions will also address the pharmacokinetic properties of ralinepag, its tolerability, and how it compares to existing PAH therapies.

The meeting will feature presentations from leading experts in the field of pulmonary hypertension, including members of the ADVANCE OUTCOMES Steering Committee. Attendees will have opportunities for networking and engaging in Q&A sessions to gain deeper insights into the clinical development program of ralinepag and its implications for patient care.

Healthcare professionals, researchers, patient advocates, and industry representatives involved in the management and treatment of PAH are encouraged to attend. This meeting will provide valuable information on a potential new therapeutic option and offer a forum for discussing its impact on current treatment paradigms.